[Current treatment of Parkinson's disease: problems and controversies].
Treating patients with Parkinson's disease is not an easy task for the physician who is facing a disease well responsive to symptomatic therapy, yet escaping any curative approaches. In spite of the large therapeutic armamentarium available, many issues remained unsolved, as indications of a particular therapeutic agent are only loosely defined and evolving according to various parameters such as disease progression and severity, the profile of potentially serious adverse effects, the physician's level of expertise and patient's expectations. The growing experience acquired with subthalamic nucleus deep brain stimulation has shown that indications for such a surgery have to be cautiously examined. After initial therapeutic enthusiasm, we are now at a time of problems and controversies.
Service de neurologie Département Neuclid HUG, 1211 Genève 14. Pierre.Burkhard@hcuge.ch
P R
PR
Burkhard
J-G
JG
Villemure
F J G
FJ
Vingerhoets
D000978:Antiparkinson Agents / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D010300:Parkinson Disease / Q000628:therapy*
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D018727:Muscarinic Antagonists; D007980:Levodopa